Skip to main content
Journal cover image

Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.

Publication ,  Journal Article
White, HD; Ohman, EM; Lincoff, AM; Bertrand, ME; Colombo, A; McLaurin, BT; Cox, DA; Pocock, SJ; Ware, JA; Manoukian, SV; Lansky, AJ; Mehran, R ...
Published in: J Am Coll Cardiol
September 2, 2008

OBJECTIVES: This study was designed to determine the impact of bivalirudin on 1-year outcomes in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). BACKGROUND: The ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial demonstrated that in moderate- and high-risk ACS patients undergoing PCI, bivalirudin alone compared to unfractionated heparin (UFH) or enoxaparin plus a glycoprotein (GP) IIb/IIIa inhibitor resulted in less major bleeding and similar ischemic outcomes at 30 days. The impact of bivalirudin on 1-year outcomes in ACS patients undergoing PCI is unknown. METHODS: In the ACUITY trial, 13,819 patients were enrolled, and 7,789 (56.4%) patients had PCI. Composite ischemia (death, myocardial infarction, or unplanned revascularization) and mortality at 1 year were assessed. RESULTS: Among patients undergoing PCI, 2,561, 2,609, and 2,619 were randomized to UFH or enoxaparin plus a GP IIb/IIIa inhibitor, bivalirudin plus a GP IIb/IIIa inhibitor, and bivalirudin monotherapy, respectively. At 1 year, there were no differences in composite ischemia (17.8% vs. 19.4% vs. 19.2%, p = NS) or mortality (3.2% vs. 3.3% vs. 3.1%, p = NS) among the 3 groups, respectively. CONCLUSIONS: Bivalirudin compared with UFH or enoxaparin plus a GP IIb/IIIa inhibitor results in similar rates of composite ischemia and mortality at 1 year in moderate- and high-risk ACS patients undergoing PCI.

Duke Scholars

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

September 2, 2008

Volume

52

Issue

10

Start / End Page

807 / 814

Location

United States

Related Subject Headings

  • Time Factors
  • Risk Factors
  • Recombinant Proteins
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Peptide Fragments
  • Middle Aged
  • Male
  • Humans
  • Hirudins
  • Heparin
 

Citation

APA
Chicago
ICMJE
MLA
NLM
White, H. D., Ohman, E. M., Lincoff, A. M., Bertrand, M. E., Colombo, A., McLaurin, B. T., … Stone, G. W. (2008). Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol, 52(10), 807–814. https://doi.org/10.1016/j.jacc.2008.05.036
White, Harvey D., E Magnus Ohman, A Michael Lincoff, Michel E. Bertrand, Antonio Colombo, Brent T. McLaurin, David A. Cox, et al. “Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.J Am Coll Cardiol 52, no. 10 (September 2, 2008): 807–14. https://doi.org/10.1016/j.jacc.2008.05.036.
White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin BT, Cox DA, Pocock SJ, Ware JA, Manoukian SV, Lansky AJ, Mehran R, Moses JW, Stone GW. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol. 2008 Sep 2;52(10):807–814.
Journal cover image

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

September 2, 2008

Volume

52

Issue

10

Start / End Page

807 / 814

Location

United States

Related Subject Headings

  • Time Factors
  • Risk Factors
  • Recombinant Proteins
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Peptide Fragments
  • Middle Aged
  • Male
  • Humans
  • Hirudins
  • Heparin